Whitehawk Therapeutics, Inc.
$4.23
▼
-0.85%
2026-04-21 10:16:00
ir.whitehawktx.com
NCM: WHWK
Explore Whitehawk Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$193.98 M
Current Price
$4.23
52W High / Low
$4.48 / $1.39
Stock P/E
—
Book Value
$2.89
Dividend Yield
—
ROCE
-83.93%
ROE
-21.82%
Face Value
—
EPS
$-0.33
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
23
Beta
0.62
Debt / Equity
0
Current Ratio
10.26
Quick Ratio
10.26
Forward P/E
-2.83
Price / Sales
22.39
Enterprise Value
$14.3 M
EV / EBITDA
-0.12
EV / Revenue
2
Rating
Buy
Target Price
$5.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lunai Bioworks Inc. | $0.34 | — | $12.33 M | — | 88.63% | -3.66% | $5.5 / $0.15 | $-0.56 |
| 2. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
| 3. | Theravance Biopharma, Inc. | $16.72 | 8.29 | $877.44 M | — | -0.81% | 44.84% | $21.03 / $8.33 | $5.81 |
| 4. | Vistagen Therapeutics, Inc. | $0.61 | — | $24.12 M | — | -78.03% | -1.02% | $5.14 / $0.43 | $1.28 |
| 5. | Seres Therapeutics, Inc. | $8.94 | 15.05 | $85.7 M | — | -79.05% | 19.64% | $29.98 / $6.53 | $4.63 |
| 6. | Scholar Rock Holding Corporation | $47.8 | — | $5.49 B | — | -110.26% | -1.23% | $51.62 / $27.07 | $2.26 |
| 7. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 7.14 M | 7.24 M | — |
| Operating Profit | -24.89 M | -19.55 M | -54.75 M | -15.22 M | -18.95 M | — |
| Net Profit | -23.25 M | -17.75 M | -52.62 M | 73.02 M | -18.27 M | — |
| EPS in Rs | -0.49 | -0.38 | -1.11 | 1.55 | -0.39 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 7.14 M | 25.98 M | 24.35 M | 15.22 M |
| Operating Profit | -114.4 M | -64.82 M | -71.93 M | -58.96 M |
| Net Profit | -20.6 M | -63.69 M | -65.77 M | -60.51 M |
| EPS in Rs | -0.44 | -1.35 | -1.39 | -1.28 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 150.83 M | 70.32 M | 132.42 M | 184.24 M |
| Total Liabilities | 14.52 M | 17.84 M | 27.23 M | 25.86 M |
| Equity | 136.31 M | 52.48 M | 105.19 M | 158.38 M |
| Current Assets | 149.01 M | 61.29 M | 124.59 M | 180.03 M |
| Current Liabilities | 14.52 M | 17.07 M | 26.39 M | 18.84 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -97.43 M | -59.55 M | -59.66 M | -49.64 M |
| Investing CF | 11.89 M | 25.2 M | 83.21 M | -132.89 M |
| Financing CF | 94.38 M | 0.13 M | 0.33 M | 72.62 M |
| Free CF | -97.98 M | -61.2 M | -63.63 M | -50.08 M |
| Capex | -0.55 M | -1.65 M | -3.97 M | -0.44 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 6.69% | 60.06% | — | — |
| Earnings Growth % | 3.15% | -8.68% | — | — |
| Profit Margin % | -245.13% | -270.04% | -397.69% | — |
| Operating Margin % | -249.47% | -295.36% | -387.47% | — |
| Gross Margin % | 88.36% | 88.47% | 91.23% | — |
| EBITDA Margin % | -243.79% | -268.4% | -395.14% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2021-08-27 | 1:0.0666667 |